Research Article
VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study
Published Online:22 Dec 2010https://doi.org/10.2217/pgs.10.162
Abstract
Aim: A total of 371 patients under stable warfarin therapy were retrospectively selected to develop a pharmacogenetic algorithm to identify the individual maintenance dose. Materials & methods: The variables that were entered into the algorithm were: VKORC1, CYP2C9 and CYP4F2 polymorphisms, body surface area and age. Results: The percentage of cases whose predicted mean weekly warfarin dose was within 20% of the actual maintenance dose was 51.8% considering patients overall, and were 36.2, 66.2 and 55.4%, respectively, taking into account patients requiring low (≤25 mg/week), intermediate (25–45 mg/week) and high (≥45 mg/week) doses. The algorithm could correctly assign 73.8 and 63.2% of patients to the low- and high-dose regimens, respectively. We developed and validated a pharmacogenetic algorithm in a series of Italian patients, we then tested, in the same series of italian patients, the formulas of three published algorithms. These three algorithms were developed and validated by their authors in a series of patients different from our own. The performance of our algorithm in our patients series was slightly higher than that achieved when using the three other algorithms in our patients series. Conclusion: The high predictive accuracy of low and high warfarin requirements of our algorithm warrants its application in prospective studies for clinical validation.
Papers of special note have been highlighted as: ▪ of interest
Bibliography
- 1 Eby CS: Counterpoint: pharmacogenetic-based initial dosing of warfarin: not ready for prime time. Clin. Chem.55,712–714 (2009).
- 2 Pengo V, Pegoraro C, Cucchini U, Iliceto S: Worldwide management of oral anticoagulant therapy: the ISAM study. J. Thromb. Thrombolysis21,73–77 (2006).
- 3 D’Andrea G, D’Ambrosio R, Margaglione M: Oral anticoagulants: pharmacogenetics relationship between genetic and nongenetic factors. Blood Rev.22,127–140 (2008).
- 4 Oldenburg J, Marinova M, Müller-Reible C, Watzka M: The vitamin K cycle. Vitam. Horm.78,35–62 (2008).
- 5 McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE: CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol.75,1337–1346 (2009).▪ First paper to describe the pathophysiology underlying the correlation between the CYP4F2 V433M variant and warfarin dosing.
- 6 Palareti G, Leali N, Coccheri S et al.: Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet348,423–428 (1996).
- 7 Palareti G, Manotti C, D’Angelo A et al.: Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). Thromb. Haemost.78,1438–1443 (1997).
- 8 Wadelius M, Chen LY, Eriksson N et al.: Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet.121,23–34 (2007).
- 9 Takahashi H, Echizen H: Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet.40,587–603 (2001).
- 10 Yin T, Miyata T: Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 – rationale and perspectives. Thromb. Res.120,1–10 (2007).
- 11 Lindh JD, Holm L, Andersson ML, Rane A: Influence of CYP2C9 genotype on warfarin dose requirements – a systematic review and meta-analysis. Eur. J. Clin. Pharmacol.65,365–375 (2009).
- 12 Takeuchi F, McGinnis R, Bourgeois S et al.: A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet.5,e1000433 (2009).
- 13 Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR: Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics4,39–42 (1994).
- 14 Sullivan-Klose TH, Ghanayem BI, Bell DA et al.: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics6,341–349 (1996).
- 15 Lindh JD, Lundgren S, Holm L, Alfredsson L, Rane A: Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin. Pharmacol. Ther.78,540–550 (2005).
- 16 Higashi MK, Veenstra DL, Kondo LM et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA287,1690–1698 (2002).
- 17 McClain MR, Palomaki GE, Piper M, Haddow JE: A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet. Med.10,89–98 (2008).
- 18 Limdi NA, Wadelius M, Cavallari L et al.: Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across three racial groups. Blood115,3827–3834 (2010).▪ Influence of VKORC1 polymorphism in warfarin dose was captured by a single polymorphism (-1639G>A or 1173C>T) across different racial groups.
- 19 Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadée W: Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood112,1013–1021 (2008).
- 20 Caldwell MD, Awad T, Johnson JA et al.: CYP4F2 genetic variant alters required warfarin dose. Blood111,4106–4112 (2008).
- 21 Borgiani P, Ciccacci C, Forte V et al.: CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics10,261–266 (2009).
- 22 Pautas E, Moreau C, Gouin-Thibault I et al.: Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin. Pharmacol. Ther.87,57–64 (2010).
- 23 Au N, Rettie AE: Pharmacogenomics of 4-hydroxycoumarin anticoagulants. Drug. Metab. Rev.40,355–375 (2008).
- 24 Kim MJ, Huang SM, Meyer UA, Rahman A, Lesko LJ: A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J. Clin. Pharmacol.49,138–146 (2009).
- 25 Lubitz SA, Scott SA, Rothlauf EB et al.: Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J. Thromb. Haemost.8,1018–1026 (2010).▪ Comparison of the clinical performance of 12 different published algorithms.
- 26 D’Andrea G, D’Ambrosio RL, Di Perna P et al.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood105,645–649 (2005).
- 27 Takahashi H, Wilkinson GR, Nutescu EA et al.: Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African–Americans. Pharmacogenet. Genomics16,101–110 (2006).
- 28 Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, Novelli G: Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics8,1545–1550 (2007).
- 29 Limdi NA, Veenstra DL: Warfarin pharmacogenetics. Pharmacotherapy28,1084–1097 (2008).
- 30 Schelleman H, Limdi NA, Kimmel SE: Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics9,1331–1346 (2008).
- 31 Wadelius M, Chen LY, Lindh JD et al.: The largest prospective warfarin-treated cohort supports genetic forecasting. Blood113,784–792 (2009).▪ Clinical evidence that supports that initiation of warfarin guided by pharmacogenetics improves outcome.
- 32 International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB et al.: Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med.360,753–764 (2009).▪ Largest multicentric and multiethnic study for validation of pharmacogenetic warfarin dosing algorithm.
- 33 Anderson JL, Horne BD, Stevens SM et al.: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation116,2563–2570 (2007).
- 34 Limdi NA, Beasley TM, Crowley MR et al.: VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African–Americans and European–Americans. Pharmacogenomics9,1445–1458 (2008).
- 35 Carrillo JA, Benitez J: Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin. Pharmacokinet.39,127–153 (2000).
- 36 Djordjevic N, Ghotbi R, Bertilsson L, Jankovic S, Aklillu E: Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur. J. Clin. Pharmacol.64,381–385 (2008).
- 37 Ammar HO, Ghorab M, el-Nahhas SA, Makram TS: Interaction of oral anticoagulants with methyl xanthines. Pharmazie52,946–950 (1997).
- 38 Prati D, Taioli E, Zanella A et al.: Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med.137,1–10 (2002).
- 39 Cavallari LH, Langaee TY, Momary KM et al.: Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin. Pharmacol. Ther.87,459–464 (2010).
- 40 Perini JA, Struchiner CJ, Silva-Assunção E, Suarez-Kurtz G: Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin. Pharmacol. Ther.87,417–420 (2010).
- 41 Harrington DJ, Gorska R, Wheeler R et al. : Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J. Thromb. Haemost.6,1663–1670 (2008).
- 101 Italian Medicines Agency www.agenziafarmaco.it/allegati/rapporto_osmed_2008.pdf
- 102 US FDA: Coumadin® tablets www.accessdata.fda.gov/drugsatfda_docs/label/2007/009218s105lblv2.pdf
- 103 Human CYP450 Allele Nomenclature Committee www.imm.ki.se/CYPalleles/
- 104 CYP2C9 allele nomenclature www.cypalleles.ki.se/cyp2c9.htm
